from the Utrecht Medical Centre in The Netherlands provides the first clinical evidence, to the authors' knowledge, that local interleukin-2 (IL-2) therapy in combination with radiotherapy is an ...

Interleukin 2 (IL-2) is the only systemic treatment currently ... who develop progressive disease after cytokine therapy”. In the commentary of the paper on sunitinib, however, Stadler and ...

MedStar Georgetown University Hospital is the first hospital in the Washington metropolitan area to offer Tumor-Infiltrating ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

The drug, SAR444245, is part of an emerging class of cancer immunotherapies based on interleukin-2 (IL-2 ... Use of the one FDA-approved IL-2 therapy is limited by its toxicity.

Immunotherapy represents a groundbreaking approach to combating various diseases by harnessing and enhancing the body’s ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...